Non-alcoholic fatty liver disease (NAFLD) is a clinical-pathological condition with a wide spectrum of histologic abnormalities and clinical outcomes. While hepatic steatosis alone is a benign condition, non- alcohol steatohepatatis (NASH) is the most serious form of NAFLD and is characterized by the histologic findings of alcoholic hepatitis occurring in patients who deny significant alcohol intake. The prevalence of NASH is estimated to be 3% in the general population and up to 20% in patients with type II diabetes and obesity; thereby making NASH the most common form of chronic liver disease in the United States. Over a 10-year period cirrhosis develops in 25% of NASH patients with a liver related mortality of 10%. The pathogenesis of NASH has been proposed to occur in two steps. The first step involves insulin resistance, which causes hepatic seatosis. The second sep involves lipid-laden hepatocytes that serve as a substrate for oxidative stress, which via lipid peroxidation and inflammatory cytokines, results in fibrosis and hepatocyte necrosis. Short duration and small sample size of previous NASH clinical trials have limited these trials from obtaining valid end points. Consequently the therapy of NASH remains uncertain. Therefore, the overall objective of this grant is twofold. The first is to create an infrastructure for patient recruitment and retention in large multi-center trials using carefully defined and uniform criteria for the diagnosis of NASH. The second is to evaluate different therapies directed at both pathogenic steps in NAS. A show-term (6-month) trial will attempt to improve insulin sensitivity by decreasing visceral fat with diet alone or diet plus exercise. In a long-term (3-year) trial, two different doses of vitamin E will be used to reduce oxidative stress and decrease fibrosis. Although both studies could not performed as independent trials, it is anticipated that by performing these trials in series and treating both pathogenetic steps (as proposed), an optimal therapeutic response will be obtained.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DK061732-05
Application #
7038341
Study Section
Special Emphasis Panel (ZDK1-GRB-7 (J1))
Program Officer
Robuck, Patricia R
Project Start
2002-06-15
Project End
2009-04-30
Budget Start
2006-05-01
Budget End
2007-04-30
Support Year
5
Fiscal Year
2006
Total Cost
$520,786
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Ajmera, Veeral; Belt, Patricia; Wilson, Laura A et al. (2018) Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. Clin Gastroenterol Hepatol 16:1511-1520.e5
Dasarathy, Srinivasan; Hatzoglou, Maria (2018) Hyperammonemia and proteostasis in cirrhosis. Curr Opin Clin Nutr Metab Care 21:30-36
Lindenmeyer, Christina C; McCullough, Arthur J (2018) The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. Clin Liver Dis 22:11-21
Rausch, John C; Lavine, Joel E; Chalasani, Naga et al. (2018) Genetic Variants Associated With Obesity and Insulin Resistance in Hispanic Boys With Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr 66:789-796
Vuppalanchi, Raj; Siddiqui, Mohammad S; Van Natta, Mark L et al. (2018) Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology 67:134-144
Hajifathalian, Kaveh; Torabi Sagvand, Babak; McCullough, Arthur J (2018) Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study. Hepatology :
Brunt, Elizabeth M; Kleiner, David E; Wilson, Laura A et al. (2018) Improvements in Histologic Features and Diagnosis associated with Improvement in Fibrosis in NASH: Results from the NASH Clinical Research Network Treatment Trials. Hepatology :
Harlow, Kathryn E; Africa, Jonathan A; Wells, Alan et al. (2018) Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease. J Pediatr 198:76-83.e2
Middleton, Michael S; Van Natta, Mark L; Heba, Elhamy R et al. (2018) Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology 67:858-872
Hameed, B; Terrault, N A; Gill, R M et al. (2018) Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 47:645-656

Showing the most recent 10 out of 112 publications